Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Woyach, Jennifer A., Furman, Richard R., Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arletta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J., Chang, Betty Y., Johnson, Amy J., Byrd, John C.·2014·New England Journal of Medicine
DOI 10.1056/nejmoa1400029

Cited by (1,276)

Items 201–300 of 1,276

  1. Mechanisms of tumor cell resistance to the current targeted-therapy agents
    G. Khamisipour, Farhad Jadidi-Niaragh, A. S. Jahromi, K. Zandi, M. Hojjat-Farsangi · 2016 · Tumor Biology
  2. Therapeutic options for relapsed/refractory mantle cell lymphoma
    Toby Andrew Eyre, Chan Yoon Cheah, Michael L. Wang · 2021 · Blood
  3. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
    Fansheng Ran, Yun Liu, Chen Wang, Zhongyuan Xu, Yanan Zhang, Yang Liu, Guisen Zhao, Yong Ling · 2021 · European Journal of Medicinal Chemistry
  4. Chronic lymphocytic leukaemia
    Nitin Jain, William G. Wierda, Susan Mary O'Brien · 2024 · The Lancet
  5. Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer’s disease
    Tsai, Andy P., Dong, Chuanpeng, Lin, Peter Bor-Chian, Oblak, Adrian L., Viana Di Prisco, Gonzalo, Wang, Nian, Hajicek, Nicole, Carr, Adam J., Lendy, Emma K., Hahn, Oliver et al. · 2023 · Immunity
  6. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
    Rachel Thijssen, Johanna ter Burg, Brett Garrick, Gregor G. W. van Bochove, Jennifer R. Brown, Stacey M. Fernandes, María Solé Rodriguez, Jean‐Marie Michot, Michael J. Hallek, Barbara F. Eichhorst et al. · 2016 · Blood
  7. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
    Matthew Steven Davids, Danielle M. Brander, Haesook T. Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M. Hellman, Josie Bazemore, Karen Francoeur, Alvaro Jose Alencar et al. · 2019 · The Lancet Haematology
  8. The Development of BTK Inhibitors: A Five-Year Update
    Bruno Tasso, Andrea Spallarossa, Eleonora Russo, Chiara Brullo · 2021 · Molecules
  9. Recent Advances in PROTACs for Drug Targeted Protein Research
    Tingting Yao, Heng Xiao, Hong Wang, Xiaowei Xu · 2022 · International Journal of Molecular Sciences
  10. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
    Lennart Brewitz, Leo Dumjahn, Yilin Zhao et al. · 2023 · Journal of Medicinal Chemistry
  11. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
    Jones, D, Woyach, J A, Zhao, W, Caruthers, S, Tu, H, Coleman, J, Byrd, J C, Johnson, A J, Lozanski, G · 2017 · Leukemia
  12. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study
    Narendranath Epperla, Mehdi Hamadani, Amanda F. Cashen, Kwang Woo Ahn, Eunhye Oak, Abraham Sebastian Kanate, Oscar Calzada, Jonathon Brett Cohen, Luke Farmer, Nilanjan Ghosh et al. · 2017 · Hematological Oncology
  13. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
    Kerry Anne Rogers, Leslie Ann Andritsos, Lai Wei, Eric M. McLaughlin, Amy S. Ruppert, Mirela Iulia Anghelina, James Stewart Blachly, Timothy G. Call, Dai Chihara, Anees M. Dauki et al. · 2021 · Blood
  14. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
    Silvia Bonfiglio, Lesley‐Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander et al. · 2023 · Blood Advances
  15. Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
    Qi Wang, Yakov Pechersky, Shiori Sagawa, Albert C. Pan, David Elliot Shaw · 2019 · Proceedings of the National Academy of Sciences
  16. Critical molecular pathways in CLL therapy
    Gerardo Ferrer, Emili Montserrat · 2018 · Molecular Medicine
  17. The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
    Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski · 2022 · Cancers
  18. PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
    Klaus Okkenhaug, Jan A. Burger · 2015 · Current topics in microbiology and immunology
  19. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
    Viralkumar M. Patel, Kumudha Balakrishnan, Mark Douglas, Thomas T. Tibbitts, Ethan Xu, Jeffery Lorne Kutok, Mark Ayers, Aloke Kumar Sarkar, Renato A. Guerrieri, William G. Wierda et al. · 2016 · Leukemia
  20. PLCγ1: Potential arbitrator of cancer progression
    Hyun‐Jun Jang, Pann‐Ghill Suh, Yu Jin Lee · 2017 · Advances in Biological Regulation
  21. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
    Matthew D. Blunt, Stefan Koehrer, Rachel C. Dobson, Marta Larráyoz, Sarah Wilmore, Alice Hayman, Jack Parnell, Lindsay D. Smith, Andrew John Davies, Peter Johnson et al. · 2016 · Clinical Cancer Research
  22. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
    Varinder Kaur, Arjun Swami · 2017 · Annals of Hematology
  23. Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies
    Richard Rosenquist, Sı́lvia Beà, Ming‐Qing Du, Bertrand Nadel, Qiang Pan‐Hammarström · 2017 · Journal of Internal Medicine
  24. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia
    Elisa ten Hacken, Maria Gounari, Paolo Ghia, Jan A. Burger · 2018 · Leukemia
  25. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
    C. I. Edvard Smith, Jan A. Burger · 2021 · Frontiers in Immunology
  26. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
    Hsu-Ping Kuo, Scott A. Ezell, Karl J. Schweighofer, Leo W.K. Cheung, Sidney Hsieh, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Ssucheng J. Hsu, Chun‐Te Chen et al. · 2017 · Molecular Cancer Therapeutics
  27. Targeting BCL-2 in B-cell lymphomas
    Matthew Steven Davids · 2017 · Blood
  28. Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
    Philip A. Thompson, Jan A. Burger · 2017 · Expert Opinion on Investigational Drugs
  29. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
    Andrew R. Lavik, Fei Zhong, Ming-Jin Chang, Edward F. Greenberg, Yuvraj Choudhary, Mitchell Reed Smith, Karen S. McColl, John J. Pink, Frederic J. Reu, Shigemi Matsuyama et al. · 2015 · Oncotarget
  30. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
    Sean D. Reiff, Elizabeth M. Muhowski, Daphne Guinn, Amy Lehman, Catherine A. Fabian, Carolyn M. Cheney, Rose Mantel, Lisa Smith, Amy Jo Johnson, Wendy B. Young et al. · 2018 · Blood
  31. Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
    Lenka Sedlaříková, Anna Petráčková, Tomáš Papajík, Peter Turcsányi, Eva Kriegová · 2020 · Frontiers in Oncology
  32. How to unleash mitochondrial apoptotic blockades to kill cancers?
    Jing Deng · 2016 · Acta Pharmaceutica Sinica B
  33. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
    Aneel Paulus, Sharoon Akhtar, Thomas R. Caulfield, Kelara Samuel, Hamza Yousaf, Yamima Bashir, Shumail M. Paulus, D Tran, Roman Hudec, Davitte Cogen et al. · 2016 · Blood Cancer Journal
  34. Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
    Emily M. McWilliams, Christopher R. Lucas, Timothy Frank Chen, Bonnie K. Harrington, Ronni Wasmuth, Amanda R. Campbell, Kerry Anne Rogers, Carolyn M. Cheney, Xiaokui Molly Mo, Leslie Ann Andritsos et al. · 2019 · Blood Advances
  35. Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine
    Senthilkumar Damodaran, Michael F. Berger, Sameek Roychowdhury · 2015 · American Society of Clinical Oncology Educational Book
  36. Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
    Jeff Porter Sharman, Charles Michael Farber, Daruka Mahadevan, Marshall T. Schreeder, Heather Dawn Brooks, Kathryn S. Kolibaba, Suzanne R. Fanning, Leonard M. Klein, Daniel Reif Greenwald, Peter Sportelli et al. · 2016 · British Journal of Haematology
  37. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
    Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Jh. SUKHANOVA, Girish Venkataraman, Shengjian Huang, Hui Zhang, Mir Basharath Alikhan et al. · 2018 · Blood Advances
  38. PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants
    Baysac, Kathleen, Sun, Guangping, Nakano, Hiroto, Schmitz, Elizabeth G., Cruz, Anthony C., Fisher, Charles, Bailey, Alexis C., Abbott, Jordan K., Aldave Becerra, Juan Carlos, Allenspach, Eric J. et al. · 2024 · Journal of Allergy and Clinical Immunology
  39. Development of covalent inhibitors: Principle, design, and application in cancer
    Zheng, Lang, Li, Yang, Wu, Defa, Xiao, Huan, Zheng, Shilong, Wang, Guan, Sun, Qiu · 2023 · MedComm – Oncology
  40. Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
    Hamasy, A, Wang, Q, Blomberg, K E M, Mohammad, D K, Yu, L, Vihinen, M, Berglöf, A, Smith, C I E · 2017 · Leukemia
  41. Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2
    Guangyan Du, Jie Jiang, Qibiao Wu, Nathaniel J. Henning, Katherine A. Donovan, Hong Yue, Jianwei Che, Wenchao Lu, Eric S. Fischer, Nabeel M. Bardeesy et al. · 2021 · Angewandte Chemie International Edition
  42. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
    Arthur L. Shaffer, James D. Phelan, James Q. Wang, Dawei Huang, George W. Wright, Monica Kasbekar, Jaewoo Choi, Ryan M. Young, Daniel E. Webster, Yandan Yang et al. · 2021 · Blood Cancer Discovery
  43. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
    Tadeusz Robak, Krzysztof Warzocha, Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Mugutdinovich Abdulkadyrov, Javier Loscertales, Iryna Kriachok, Janusz S. Kloczko, Grygoriy Rekhtman et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
  44. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
    Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo, Andrea Spallarossa · 2021 · International Journal of Molecular Sciences
  45. Targeting Gatekeeper Mutations for Kinase Drug Discovery
    Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu · 2022 · Journal of Medicinal Chemistry
  46. Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies
    Y Wang, Lili Zhang, RE Champlin, Wang Ml · 2015 · Clinical Pharmacology & Therapeutics
  47. Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia
    Grégory Lazarian, Romain Guièze, Catherine J. Wu · 2017 · Journal of Clinical Oncology
  48. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms
    Arantza Onaindía, Leonard Jeffrey Medeiros, Keyur Pravinchandra Patel · 2017 · Modern Pathology
  49. Targeting the B cell receptor pathway in non-Hodgkin lymphoma
    Kelly Valla, Christopher R. Flowers, Jean Louise Koff · 2018 · Expert Opinion on Investigational Drugs
  50. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
    Xiaoyun Lu, Jeff Bruce Smaill, Ke Ding · 2020 · Journal of Medicinal Chemistry
  51. Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
    Katharine Louise Lewis, Chan Yoon Cheah · 2021 · Journal of Personalized Medicine
  52. The clinical implications of gene mutations in chronic lymphocytic leukaemia
    Davide Rossi, Gianluca Gaïdano · 2016 · British Journal of Cancer
  53. Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
    Burcu Aslan, Görkem Kısmalı, LaKesla R. Iles, Ganiraju C. Manyam, Mary Ayres, Lisa S. Chen, Mihai Gagea, Maria Teresa Sabrina Bertilaccio, William G. Wierda, Varsha V. Gandhi · 2022 · Blood Cancer Journal
  54. E3 ligase ligand optimization of Clinical PROTACs
    Hanrui Jiang, Huan Xiong, Shuang-Xi Gu, Mingliang Wang · 2023 · Frontiers in Chemistry
  55. Structural basis for the activation of PLC-gamma isozymes by phosphorylation and cancer-associated mutations
    Nicole Hajicek, John Sondek · 2019 · Worldwide Protein Data Bank
  56. Lysine-Reactive N-Acyl-N-aryl Sulfonamide Warheads: Improved Reaction Properties and Application in the Covalent Inhibition of an Ibrutinib-Resistant BTK Mutant
    Masaharu Kawano, Syunsuke Murakawa, Kenji Higashiguchi, Kenji Matsuda, Tomonori Tamura, Itaru Hamachi · 2023 · Journal of the American Chemical Society
  57. From identification of the BTK kinase to effective management of leukemia
    C I E Smith · 2016 · Oncogene
  58. Development of BTK inhibitors for the treatment of B-cell malignancies
    Hyung-Ook Kim · 2019 · Archives of Pharmacal Research
  59. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Ilaria Del Giudice, Sara Raponi, Irene Della Starza, Maria Stefania De Propris, Marzia Cavalli, Lucia Anna De Novi, Luca Vincenzo Cappelli, Caterina Ilari, Luciana Cafforio, Anna Rita Guarini et al. · 2019 · Frontiers in Oncology
  60. Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations
    Martín-Nalda, Andrea, Fortuny, Claudia, Rey, Lourdes, Bunney, Tom D., Alsina, Laia, Esteve-Solé, Ana, Bull, Daniel, Anton, Maria Carmen, Basagaña, María, Casals, Ferran et al. · 2020 · Journal of Clinical Immunology
  61. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma
    Yunxia Liu, Shuichi Kimpara, Nguyet Minh Hoang, Anusara Daenthanasanmak, Yangguang Li, Li Lü, Vu N. Ngo, Paul D. Bates, Longzhen Song, Xiaoyue Gao et al. · 2023 · Blood
  62. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
    Aneel Paulus, Sharoon Akhtar, Hamza Yousaf, Alak Manna, Shumail M. Paulus, Yamima Bashir, Thomas R. Caulfield, Maja K. Blake, Kasyapa S. Chitta, Xingchen Wang et al. · 2017 · Blood Cancer Journal
  63. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
    Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Johannes Bloehdorn, Paolo Ghia, Anella Yahiaoui, Anna Dolnik, Tamara J. Blätte, Lars Bullinger, Rashmi Priyadharshini Dheenadayalan et al. · 2019 · Blood
  64. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib
    Gángó, Ambrus, Alpár, Donát, Galik, Bence, Marosvári, Dóra, Kiss, Richárd, Fésüs, Viktória, Aczél, Dóra, Eyüpoglu, Ediz, Nagy, Noémi, Nagy, Ákos et al. · 2020 · International Journal of Cancer
  65. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
    Sigrid Strand Skånland, Anthony R. Mato · 2021 · Blood Advances
  66. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
    Hussein A. Abbas, William G. Wierda · 2021 · Frontiers in Oncology
  67. Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
    Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks, Odilia B. J. Corneth · 2021 · Drugs
  68. Covalent drugs targeting histidine – an unexploited opportunity?
    Jianwei Che, Lyn H. Jones · 2022 · RSC Medicinal Chemistry
  69. PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
    Dalia El‐Gamal, Katie Williams, Taylor D. LaFollette, Matthew J. Cannon, James Stewart Blachly, Yiming Zhong, Jennifer Ann Woyach, Erich Williams, Farrukh Tauseef Awan, Jeffrey J. Jones et al. · 2014 · Blood
  70. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
    Guo, Ailin, Lu, Pin, Coffey, Greg, Conley, Pamela, Pandey, Anjali, Wang, Y. Lynn · 2017 · Oncotarget
  71. Targeting Protein Kinases Degradation by PROTACs
    Fei Yu, Ming Cai, Liang Shao, Jihong Zhang · 2021 · Frontiers in Chemistry
  72. How I manage ibrutinib-refractory chronic lymphocytic leukemia
    Jennifer Ann Woyach · 2017 · Blood
  73. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
    Núria Profitós-Pelejà, Juliana Carvalho Santos, Ana Marín‐Niebla, Gaël Roué, Marcelo Lima Ribeiro · 2022 · Cancers
  74. The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein
    Walliser, Claudia, Hermkes, Elisabeth, Schade, Anja, Wiese, Sebastian, Deinzer, Julia, Zapatka, Marc, Désiré, Laurent, Mertens, Daniel, Stilgenbauer, Stephan, Gierschik, Peter · 2016 · Journal of Biological Chemistry
  75. Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
    Jingyu Zhang, Jinxin Che, Xiaomin Luo, Mingfei Wu, Weijuan Kan, Yuheng Jin, Hanlin Wang, Ao Pang, Cong Li, Wenhai Huang et al. · 2022 · Journal of Medicinal Chemistry
  76. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma
    Jennifer Ann Woyach, Deborah Marie Stephens, Ian W. Flinn, Seema Ali Bhat, Ronald E. Savage, Feng Chai, Sudharshan Eathiraj, Sean D. Reiff, Elizabeth M. Muhowski, Lindsey Granlund et al. · 2023 · Cancer Discovery
  77. Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
    Nitin Jain, Lisa J. Croner, John Nathan Allan, Tanya Siddiqi, Alessandra Tedeschi, Xavier Camille Albert Badoux, Karl Eckert, Leo W.K. Cheung, Anwesha Mukherjee, James P. Dean et al. · 2023 · Clinical Cancer Research
  78. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
    Christopher Parrish, Gina B. Scott, G Migneco et al. · 2015 · Leukemia
  79. Reactive Chemical Probes: Beyond the Kinase Cysteinome
    Lyn H. Jones · 2018 · Angewandte Chemie International Edition
  80. Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
    Bartosz Puła, Aleksandra Gołoś, Patryk Górniak, Krzysztof Jamroziak · 2019 · Cancers
  81. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use
    Feili Chen, Diwen Pang, Hanguo Guo et al. · 2020 · Cancer Medicine
  82. Exploring the pathways to chronic lymphocytic leukemia
    Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps · 2021 · Blood
  83. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
    Zhenghao Chen, Helga Simon‐Molas, Gaspard Cretenet, Beatriz Valle‐Argos, Lindsay Smith, Francesco Forconi, Bauke V. Schomakers, Michel van Weeghel, Dean J. Bryant, Jaco A. C. van Bruggen et al. · 2022 · Blood
  84. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
    Jennifer Ann Woyach, Daniel Jones, Wojciech J. Jurczak, Tadeusz Robak, Árpád Illés, Arnon Philip Kater, Paolo Ghia, John C. Byrd, John Francis Seymour, Susan Long et al. · 2024 · Blood
  85. Development of PROTAC Degrader Drugs for Cancer
    Vesna Vetma, Suzanne O’Connor, Alessio Ciulli · 2024 · Annual Review of Cancer Biology
  86. Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
    Esther Kim, Sohita Dhillon · 2015 · Drugs
  87. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
    Prithviraj Bose, Varsha V. Gandhi, Michael J. Keating · 2016 · Expert Opinion on Drug Metabolism & Toxicology
  88. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
    Anella Yahiaoui, Sarah A. Meadows, Rick A. Sorensen, Zhi-Hua Cui, Kathleen S. Keegan, Robert Brockett, Guang Chen, Christophe Quéva, Li Li, Stacey L. Tannheimer · 2017 · PLoS ONE
  89. Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin
    Xiangjun Shi, Shengjie Song, Zejie Ding, Baibai Fan, Wan Zhen Huang, Tiantian Xu · 2019 · Journal of Pharmaceutical Sciences
  90. Approaches to mitigate the risk of serious adverse reactions in covalent drug design
    Thomas A. Baillie · 2020 · Expert Opinion on Drug Discovery
  91. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
    Valéria Buccheri, Wolney Góis Barreto, Laura Fogliatto, Marcelo Capra, Mariana Marchiani, Vanderson Rocha · 2018 · Annals of Hematology
  92. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK
    Kamaldeep Dhami, Anirban Chakraborty, Tarikere L. Gururaja, Leo W.K. Cheung, Chaohong C. Sun, Felix DeAnda, Xiaodong Huang · 2022 · Science Signaling
  93. Degraders upgraded: the rise of PROTACs in hematological malignancies
    Joshua M. L. Casan, John Francis Seymour · 2024 · Blood
  94. New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms
    Farrukh Tauseef Awan, John C. Byrd · 2014 · Clinical Cancer Research
  95. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
    Gilad Itchaki, Jennifer R. Brown · 2016 · Therapeutic Advances in Hematology
  96. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
    Josée Golay, Greta Ubiali, Martino Introna · 2017 · Haematologica
  97. Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond
    Richard Rosenquist, Andreas Rosenwald, Ming‐Qing Du, Gianluca Gaïdano, Pascal Groenen, Andrew Charles Wotherspoon, Paolo Ghia, Philippe Gaulard, Elı́as Campo, Κώστας Σταματόπουλος · 2016 · Haematologica
  98. BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
    Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González · 2021 · Cancers
  99. Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
    Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Marco Montillo, Alessandra Tedeschi · 2023 · Cancers
  100. Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease
    Garth Powis, Emmanuelle J. Meuillet, Martín Indarte, Garrett Booher, Lynn Kirkpatrick · 2023 · Biomedicine & Pharmacotherapy